Enzo Biochem has received an expansion of its Emergency Use Authorisation (EUA) from the US Food and Drug Administration (FDA) to conduct tests on pooled samples that contain up to five individual swab specimens. The tests will be conducted on the AMPIPROBE® SARS-Cov-2 Test System using three different platforms including Enzo’s GENFLEX™ automated high-throughput platform.
CytoSorbents Corporation has received medical device authorisation from Health Canada to import, sell, and use its CytoSorb blood purification technology to treat hospitalised Covid-19 patients. The company is expected to collaborate with ebbtides medical, a specialty distributor of medical products, to accelerate the availability of the therapy.
NextGen Biomed, has received approval from the Shamir Medical Centre (Asaf Harofe) Review Board for a clinical trial of its rapid breath test to detect the SARS-CoV-2 virus, as well as evaluate the efficacy of vaccines. The company will monitor the IgM and IgG antibody among those getting vaccinated for Covid-19, to assess the effectiveness of different treatments.
Innova Medical Group (IMG) has acquired California-based MPS Medical, to expand its Covid-19 rapid test kit manufacturing capacity in the US. MPS Medical is an FDA registered medical device manufacturer known for high-quality medical devices. As per the new ownership, MPS Medical will aggressively ramp up capacity for multi-millions of test kits per day in California, anticipating greater demand for domestic and international customers.